Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples